FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華潤醫藥集團有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 不適用 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 03320 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 6,282,510,461 0 6,282,510,461 增加 / 減少 (-) 本月底結存 6,282,510,461 0 6,282,510,461 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | --- | | ✔ 已符合適用的公眾持股量要求（見下方） ...

Core Viewpoint - China Resources Pharmaceutical (03320) experienced a nearly 3% decline in stock price, currently trading at HKD 4.46 with a transaction volume of HKD 25.16 million, following the profit forecast announcement from its subsidiary, China Resources Boya Biological (300294) [1] Group 1: Financial Performance - China Resources Boya Biological announced a profit forecast for the year ending December 31, 2025, estimating a net profit attributable to shareholders of approximately RMB 105 million to RMB 136.5 million, a significant decrease from the previous year's net profit of approximately RMB 397 million [1] - The forecast indicates an expected net loss attributable to shareholders, excluding non-recurring gains and losses, ranging from RMB 7.5 million to RMB 15 million, compared to a net profit of approximately RMB 302 million in the same period last year [1] Group 2: Business Challenges - The blood products business of China Resources Boya Biological is facing challenges due to factors such as expanded centralized procurement, DRG/DIP reforms, medical insurance cost control, and stringent regulation of reasonable drug use, leading to a reduction in clinical prescriptions and demand [1] - Increased market competition has resulted in a year-on-year decline in the gross profit margin of the blood products business during the reporting period [1]

Core Viewpoint - China Resources Pharmaceutical (03320) experienced a nearly 3% decline in stock price, currently trading at HKD 4.46, with a transaction volume of HKD 25.16 million. The company announced a profit forecast for its subsidiary, China Resources Boya Biopharmaceutical, indicating a significant drop in net profit for the fiscal year ending December 31, 2025, compared to the previous year [1]. Group 1 - China Resources Boya Biopharmaceutical expects a net profit attributable to shareholders of approximately RMB 105 million to RMB 136.5 million for the fiscal year ending December 31, 2025, down from RMB 397 million in the previous year [1]. - The company anticipates a net loss attributable to shareholders, excluding non-recurring gains and losses, of approximately RMB 7.5 million to RMB 15 million, compared to a net profit of RMB 302 million in the previous year [1]. - The blood products business of China Resources Boya Biopharmaceutical is facing challenges due to factors such as expanded centralized procurement, DRG/DIP reforms, medical insurance cost control, and stringent regulation of reasonable drug use, leading to a decrease in clinical prescriptions and demand [1]. Group 2 - Increased market competition has resulted in a year-on-year decline in the gross profit margin of China Resources Boya Biopharmaceutical's blood products business during the reporting period [1].

根据公开信息统计：截至30日，1月（1月1日-1月30日）募资动态共23起。 KKR开年抄底 「投资界前哨」系投资界旗下专注创投政策风向、 VC/PE 动态公众号，欢迎关注！ KKR来了。 投资界获悉，本周KKR宣布完成25亿美元（约170亿人民币）亚洲私募信贷基金募资，将重点投资于亚太地区的非公开市场 优质信贷资产。 自2019年以来，KKR通过其亚洲信贷策略已在亚太地区完成逾60笔投资项目，其中约83亿美元由KKR出资，交易总值达275 亿美元，涵盖针对医疗、教育、房地产、物流和基础设施等行业的大型企业与金融投资人提供的控股收购融资和定制化资本 解决方案。 独家|开年最大募资诞生，20亿 新年募资开始了。1月23日，恒旭资本宣布完成第四期旗舰基金的首轮关账，募集规模超20亿元人民币，计划终关规模达35 亿元，缔造开年第 一笔大额人民币募资。 在同行印象中，恒旭资本是一家拥有雄厚产业背景和资源的市场化CVC。自2019年设立以来，恒旭资本六年已收获19家上 市企业，过去一年更是接连拿下长风药业、图达通、西安奕材、瑞博生物等6个IPO，被认为是私募股权投资市场中稀缺的兼 具产业背景及市场化机制的CVC之一。 ...

报告期内，华润博雅生物预期非经常性损益对净利润的影响约为人民币1.2亿元，主要受政府补助、出 售资产及财富管理收入等因素影响。截至2024年12月31日止年度，非经常性损益为人民币9500万元。 报告期内，华润博雅生物坚定践行华润"1246"模式，凭藉"四个重塑"(价值重塑、业务重塑、组织重 塑、精神重塑)，克服复杂多变市场环境带来的困难，引领学术发展，化解历史风险，预期可实现经营 收益同比增长10.00%至25.00%，主要由于收购绿十字香港控股有限公司所致。 截至2025年12月31日止年度，归属于华润博雅生物股东的净利润大幅下降，主要由于安徽格林克医药销 售有限公司(绿十字香港控股有限公司的全资附属公司，而绿十字香港控股有限公司已于2024年11月由 华润博雅生物收购)所分销的医美产品透明质酸市况2025年有所下滑，导致产生无形资产(专营权)减值及 商誉减值合共约人民币3亿元。此外，由于收购绿十字香港控股有限公司，导致评估增值存货转售以及 资产折旧及摊销，故华润博雅生物的净利润受到影响，受影响(减少)金额约为人民币8000万元。此外， 华润博雅生物的血液制品业务受到扩大集采、DRG/DIP改革、医疗保险 ...

智通财经APP讯，华润医药(03320)发布公告，于2026年1月30日，华润博雅生物公布其截至2025年12月 31日止年度的业绩预告，其公告截至2025年12月31日止年度归属于华润博雅生物股东的净利润预计约人 民币1.05亿元至人民币1.365亿元(上年同期净利润约人民币3.97亿元)、扣除非经常性损益后归属于华润 博雅生物股东的净亏损预计约人民币750万元至人民币1500万元(上年同期净利润约人民币3.02亿元)(华 润博雅生物业绩预告)。 报告期内，华润博雅生物坚定践行华润"1246"模式，凭藉"四个重塑"(价值重塑、业务重塑、组织重 塑、精神重塑)，克服复杂多变市场环境带来的困难，引领学术发展，化解历史风险，预期可实现经营 收益同比增长10.00%至25.00%，主要由于收购绿十字香港控股有限公司所致。 截至2025年12月31日止年度，归属于华润博雅生物股东的净利润大幅下降，主要由于安徽格林克医药销 售有限公司(绿十字香港控股有限公司的全资附属公司，而绿十字香港控股有限公司已于2024年11月由 华润博雅生物收购)所分销的医美产品透明质酸市况2025年有所下滑，导致产生无形资产(专营权)减值及 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 華潤博雅生物截至2025年12月31日止年度的 業績預告 於 2026 年 1 月 30 日， 華 潤 博雅 生 物 公 佈其 截 至 2025 年 12 月31 日 止年 度 的 業績 預 告。 華潤博雅生物製藥集團股份有限公司（「華潤博雅生物」）為一家於中華人民共和國 註 冊 成 立 的 公 司 。 華 潤 博 雅 生 物 的 股 份 於 深 圳 證 券 交 易 所 上 市 。 截 至 本 公 告 日 期，華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）間接持 有華潤博雅生物總股本約30.48 %及總股本約41.79 %表決權，因此華潤博雅生物為 本公司的附屬公司。 於 2026 年 1 月 30 日 ， 華 潤 博 雅 生 物 公 佈 其 截 至 2025 ...

Core Insights - China Resources Pharmaceutical Group (CR Pharmaceutical) is a leading integrated pharmaceutical company in China, ranking among the top three in overall revenue, with a CAGR of 7.5% from 2019 to 2024 [1] Group 1: Business Overview - The company specializes in pharmaceutical manufacturing and commercial distribution of medicines, nutraceutical products, and medical instruments [1] - In 1H25, revenue from TCM and healthcare products accounted for nearly 60% of drug manufacturing revenue, with notable brands like 999 and Dong-E-E-Jiao [1] - The manufacturing business achieved a CAGR of 10.4% from 2022 to 2024, driven by organic growth and M&As [1] Group 2: Mergers and Acquisitions - The company completed the acquisition of CR Jiangzhong in February 2019, holding 43% equity in Jiangzhong Pharmaceutical, enhancing its position in the TCM industry [2] - CR Sanjiu acquired 28% equity in KPC and Tasly in December 2022 and March 2025, respectively, further consolidating its market position [2] - The company entered the blood products sector by acquiring a 29% stake in Boya Bio-Pharmaceutical in November 2021 and completed the acquisition of Nigale Technology in February 2025 [2] Group 3: Distribution Business - In 1H25, the company's distribution revenue reached Rmb110bn, ranking third in the industry [3] - The drug distribution business revenue was Rmb108.3bn, with medical device distribution revenue at Rmb18.0bn, reflecting an 8% YoY increase [3] - Retail business revenue reached Rmb5.5bn in 1H25, showing an 11% YoY growth [3] Group 4: Financial Forecast - The company is forecasted to achieve a net profit of Rmb3.49bn (+4.0% YoY) in 25E, Rmb3.76bn (+7.9% YoY) in 26E, and Rmb4.05bn (+7.7% YoY) in 27E [4] - An 8.7x 26E PE is assigned, implying a market cap of HK$35.3bn, with a 24% upside from the current market cap of HK$28.5bn [4]

Core Viewpoint - China Resources Pharmaceutical (03320) announced that its non-wholly owned subsidiary, China Resources Double Crane Pharmaceutical Co., Ltd. (Double Crane), has received a registration approval notice from the China Securities Regulatory Commission for the issuance of corporate bonds to qualified investors in the People's Republic of China [1] Group 1 - The approval notice (Zheng Jian Xu Ke [2026] No. 118) is valid for 24 months from the date of issuance [1] - Within this validity period, Double Crane is allowed to issue corporate bonds totaling RMB 3 billion [1]

Core Viewpoint - China Resources Pharmaceutical (03320) announced that its non-wholly owned subsidiary, China Resources Double Crane Pharmaceutical Co., Ltd. (600062), has received approval from the China Securities Regulatory Commission for the issuance of corporate bonds to qualified investors in the People's Republic of China [1] Group 1 - The approval notice (Zheng Jian Xu Ke [2026] No. 118) is valid for 24 months from the date of issuance [1] - Within the validity period, China Resources Double Crane can issue corporate bonds totaling RMB 3 billion [1]